Dose-dependent effect of an oral adsorbent, AST-120, in patients with early chronic renal failure.
We evaluated the dose dependence of an oral adsorbent, AST-120, in 31 patients with early chronic renal failure (baseline serum creatinine: 1.2-3.0 mg/dl). Twenty-three patients were given AST-120 and eight patients were not. AST-120 was administered at three different maintenance doses, < 3.0 g, 3.0 g and 6.0 g/day, according to patients' ability to tolerate treatment. The treatment period was 12 months. The slope of the reciprocal of serum-creatinine concentration versus time was calculated to assess the progression of renal failure. This slope became significantly less steep after AST-120 treatment at 6.0 g/day, but did not change significantly at the other doses. These findings suggest that 6.0 g/day of AST-120 may delay the initiation of dialysis in patients with early chronic renal failure.
Yorioka
N
N
Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. nyorioka@hiroshima-u.ac.jp
Ito
T
T
Masaki
T
T
Ogata
S
S
Asakimori
Y
Y
Tanji
C
C
Kyuden
Y
Y
Komiya
Y
Y
Kumagai
J
J
Taniguchi
Y
Y
Kohno
N
N
D000284:Administration, Oral; D000327:Adsorption; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002244:Carbon / Q000008:administration & dosage*; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000008:administration & dosage*; D017582:Renal Replacement Therapy; D014118:Toxins, Biological / Q000302:isolation & purification
D010087:Oxides; D014118:Toxins, Biological; C026865:uremia middle molecule toxins; D002244:Carbon; C040896:AST 120; D003404:Creatinine